Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GS-3242 in Participants With HIV-1
NCT07001319Phase 1Completed
- Sponsor
- Gilead Sciences
- Start
- May 2025
- Primary completion
- Mar 2026
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 1, open-label, single-arm trial of GS-3242 in human immunodeficiency virus type 1 infection (HIV-1), sponsored by Gilead Sciences. Primary endpoint: Change From Baseline in Plasma Human Immunodeficiency Virus (HIV)-1 Ribonucleic Acid (RNA) at Day 11. Started May 2025; status: completed.
02
Drugs
GS-3242
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT07001319.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07001319.